To include your compound in the COVID-19 Resource Center, submit it here.

Minerva’s schizophrenia miss casts doubt on approach to treating negative symptoms

Minerva’s Phase III miss in schizophrenia sent its shares down 72% on Friday, putting into doubt the future of the leading therapeutic candidate in development to treat the negative symptoms of schizophrenia -- an indication that causes much of the disability associated with the neuropsychiatric disorder.

Despite the loss of investor confidence, Minerva Neurosciences Inc.

Read the full 545 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE